Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Inflammation × Spironolactone × Clear all

Phase

Phase EARLY_PHASE1 1

Status

Sponsor Class

Study Type

Observational 1 Interventional 1

Sponsor

Conditions

Polycystic Ovary Syndrome 8 Hyperandrogenism 4 Neoplasms 3 Triple Negative Breast Neoplasms 1 Skin Diseases 1 Rare Diseases 1 Obesity 1 Neoplasm Metastasis 1 Metabolic Syndrome 1 Leukemia, Myeloid, Acute 1 Inflammation 1 Heart Failure 1 Glioblastoma 1 Endocrine System Diseases 1 Critical Illness 1 Cardiovascular Diseases 1 Cardiotoxicity 1 Advanced Malignant Neoplasm 1 Acute Kidney Injury 1 Acanthosis Nigricans 1

Interventions

Omeprazole 3 Exercise 3 salicylsalicylic acid 2 palbociclib 2 XENP 1595 2 Vitamin D 2 Tea 2 Tablets 2 Sufentanil 2 Resistance Training 2 Nutrition Assessment 2 Metformin 2 Ketorolac 2 Ibuprofen 2 Fish Oils 2 Etanercept 2 Colchicine 2 Ascorbic Acid 2 soybean oil, phospholipid emulsion 1 montelukast 1 microcrystalline cellulose 1 ginger extract 1 falcarinol 1 falcarindiol 1 epigallocatechin gallate 1 dolutegravir 1 dapagliflozin 1 Trimethoprim, Sulfamethoxazole Drug Combination 1 Sulindac 1 Spironolactone 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02689843 2019-11-12

AntiPCO

Shiraz University of Medical Sciences

Phase EARLY_PHASE1 Completed

Inflammation, Polycystic Ovary Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡